---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-065119"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2024-05-24T23:59:59+00:00"
generated_at: "2026-06-01T08:36:52.989679+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Collegium appoints Michael Heffernan interim CEO with base salary $291,666; Ciaffoni separation agreed

## Summary
- Michael Heffernan appointed Interim President and CEO effective May 24, 2024; annual base salary $291,666 (one-third of prior CEO).
- Heffernan's employment is at-will; Board may terminate at any time or extend by mutual agreement.
- Separation and Release Agreement with departing CEO Joseph Ciaffoni grants severance per employment agreement for termination without cause.

## SEC filing metadata
- accession: 0001104659-24-065119
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2024-05-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000110465924065119/0001104659-24-065119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000110465924065119/tm2415470d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-065119
- JSON: https://secwatch.observer/filing/0001104659-24-065119.json
- Plain text: https://secwatch.observer/filing/0001104659-24-065119.txt

## Key facts
- Executive change
  Michael Heffernan was appointed as Interim President and Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.
  - Action: appointed
  - Role: Interim President and Chief Executive Officer
  source text: On May 24, 2024, Collegium Pharmaceutical, Inc. (the “Company”) entered into a letter agreement (the “Letter Agreement”) with Michael Heffernan in connection with Mr. Heffernan’s appointment as Interim President and Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000110465924065119/0001104659-24-065119-index.htm
- Executive change
  Joseph Ciaffoni departed as Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.
  - Action: departed
  - Role: Chief Executive Officer
  source text: Also on May 24, 2024, the Company entered into a Separation and Release Agreement with Mr. Ciaffoni (the “Separation Agreement”) in connection with his previously announced departure from the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000110465924065119/0001104659-24-065119-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.